Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis

被引：4

作者：

Sakamori, Ryotaro ^{[1
]}

Yamada, Ryoko ^{[1
]}

Shinkai, Kazuma ^{[1
]}

Doi, Akira ^{[1
]}

Tahata, Yuki ^{[1
]}

Shigekawa, Minoru ^{[1
]}

Kodama, Takahiro ^{[1
]}

Hikita, Hayato ^{[1
]}

Yamada, Tomomi ^{[2
]}

Tatsumi, Tomohide ^{[1
]}

Takehara, Tetsuo ^{[1
]}

机构：

[1] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Suita, Osaka, Japan

[2] Osaka Univ Hosp, Dept Med Innovat, Suita, Osaka, Japan

来源：

INTERNAL MEDICINE | 2021年 / 60卷 / 05期

关键词：

ledipasvir; sofosbuvir; decompensated liver cirrhosis; skeletal muscle index (SMI); sarcopenia; direct-acting antiviral (DAA); SARCOPENIA; INFECTION;

D O I：

10.2169/internalmedicine.6029-20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hepatitis C virus (HCV) can be eliminated by direct-acting antivirals in patients with decompensated liver cirrhosis. Although viral clearance in decompensated liver cirrhosis leads to improvement of the liver function and quality of life, changes in the skeletal muscle mass after sustained virologic response (SVR) in patients with decompensated liver cirrhosis have not been reported. We present the first report of skeletal muscle mass improvement with the achievement of SVR for HCV in a 76-year-old woman with decompensated liver cirrhosis. After achieving SVR through ledipasvir/sofosbuvir treatment, the patient showed an improvement in her liver function and an increase in her skeletal muscle mass.

引用

页码：745 / 750

页数：6

共 50 条

[1] Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis
El Kassas, Mohamed
Abdeen, Nermeen
Omran, Dalia
Alboraie, Mohamed
Salaheldin, Mohamed
Eltabbakh, Mohamed
Farghaly, Rasha
Emadeldeen, Mohammed
Afify, Shimaa
Sweedy, Ahmad
Ghalwash, Ahmed
Abbass, Amr
Ezzat, Sameera
Tahoon, Marwa
ELshazly, Helmy M.
Hamdy, Hassan
Omar, Heba
[J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E877 - E882
[2] Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis
El Kassas, Mohamed
Abdeen, Nermeen
Omran, Dalia
Alboraie, Mohamed
Salaheldin, Mohamed
Eltabbakh, Mohamed
Farghaly, Rasha
Emadeldeen, Mohammed
Afify, Shimaa
Sweedy, Ahmad
Ghalwash, Ahmed
Abbass, Amr
Ezzat, Sameera
Tahoon, Marwa
ELshazly, Helmy M.
Hamdy, Hassan
Omar, Heba
[J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E877 - E882
[3] Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis
Smith, Sara K.
Rosenthal, Philip
[J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2016, 63 (05): : 516 - 517
[4] Severe chronic atopic dermatitis improvement after hepatitis C virus elimination with sofosbuvir/ledipasvir treatment
Szymanek-Pasternak, Anna
Janocha-Litwin, Justyna
Simon, Krzysztof
[J]. POSTEPY DERMATOLOGII I ALERGOLOGII, 2022, 39 (02): : 424 - 425
[5] Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation
Oya, Yuki
Sugawara, Yasuhiko
Watanabe, Takehisa
Yoshimaru, Yoko
Honda, Masaki
Hashimoto, Shintaro
Yoshii, Daiki
Isono, Kaori
Hayashida, Shintaro
Yamamoto, Hidekazu
Tanaka, Motohiko
Sasaki, Yutaka
Inomata, Yukihiro
[J]. BIOSCIENCE TRENDS, 2016, 10 (06) : 496 - 499
[6] Ledipasvir/Sofosbuvir in the Treatment of Hepatitis C Virus Genotype 6
Nguyen, Andrew A.
Weisberg, Ilan
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S368 - S368
[7] Patient With Decompensated Hepatitis C Virus-Related Cirrhosis Delisted for Liver Transplantation After Successful Sofosbuvir-Based Treatment
Ruiz, Isaac
Feray, Cyrille
Pawlotsky, Jean-Michel
Hezode, Christophe
[J]. LIVER TRANSPLANTATION, 2015, 21 (03) : 408 - 409
[8] Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis
Patel, Sonalie
Martin, Michelle T.
Flamm, Steven L.
[J]. LIVER INTERNATIONAL, 2021, 41 (12) : 3024 - 3027
[9] Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation
Everson, Gregory T.
Forns, Xavier
Mutimer, David
Manns, Michael P.
Reddy, K. Rajender
Flamm, Steven L.
Denning, Jill
Arterburn, Sarah
Brandt-Sarif, Theo
Pang, Phil
McHutchison, John G.
Afdhal, Nezam H.
Charlton, Michael R.
Samuel, Didier
Gane, Edward
[J]. TRANSPLANTATION, 2015, 99 : 101 - 101
[10] Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin
Globke, Brigitta
Raschzok, Nathanael
Teegen, Eva-Maria
Pratschke, Johann
Schott, Eckart
Eurich, Dennis
[J]. TRANSPLANT INFECTIOUS DISEASE, 2017, 19 (01)

← 1 2 3 4 5 →